Sun Kaiyuan, Tempia Stefano, Kleynhans Jackie, von Gottberg Anne, McMorrow Meredith L, Wolter Nicole, Bhiman Jinal N, Moyes Jocelyn, Carrim Maimuna, Martinson Neil A, Kahn Kathleen, Lebina Limakatso, du Toit Jacques D, Mkhencele Thulisa, Viboud Cécile, Cohen Cheryl
Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America.
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
medRxiv. 2022 Aug 22:2022.08.19.22278993. doi: 10.1101/2022.08.19.22278993.
South Africa was among the first countries to detect the SARS-CoV-2 Omicron variant. Propelled by increased transmissibility and immune escape properties, Omicron displaced other globally circulating variants within 3 months of its emergence. Due to limited testing, Omicron's attenuated clinical severity, and an increased risk of reinfection, the size of the Omicron BA.1 and BA.2 subvariants (BA.1/2) wave remains poorly understood in South Africa and in many other countries. Using South African data from urban and rural cohorts closely monitored since the beginning of the pandemic, we analyzed sequential serum samples collected before, during, and after the Omicron BA.1/2 wave to infer infection rates and monitor changes in the immune histories of participants over time. Omicron BA.1/2 infection attack rates reached 65% (95% CI, 60% - 69%) in the rural cohort and 58% (95% CI, 61% - 74%) in the urban cohort, with repeat infections and vaccine breakthroughs accounting for >60% of all infections at both sites. Combined with previously collected data on pre-Omicron variant infections within the same cohorts, we identified 14 distinct categories of SARS-CoV-2 antigen exposure histories in the aftermath of the Omicron BA.1/2 wave, indicating a particularly fragmented immunologic landscape. Few individuals (<6%) remained naïve to SARS-CoV-2 and no exposure history category represented over 25% of the population at either cohort site. Further, cohort participants were more than twice as likely to get infected during the Omicron BA.1/2 wave, compared to the Delta wave. Prior infection with the ancestral strain (with D614G mutation), Beta, and Delta variants provided 13% (95% CI, -21% - 37%), 34% (95% CI, 17% - 48%), and 51% (95% CI, 39% - 60%) protection against Omicron BA.1/2 infection, respectively. Hybrid immunity (prior infection and vaccination) and repeated prior infections (without vaccination) reduced the risks of Omicron BA.1/2 infection by 60% (95% CI, 42% - 72%) and 85% (95% CI, 76% - 92%) respectively. Reinfections and vaccine breakthroughs had 41% (95% CI, 26% - 53%) lower risk of onward transmission than primary infections. Our study sheds light on a rapidly shifting landscape of population immunity, along with the changing characteristics of SARS-CoV-2, and how these factors interact to shape the success of emerging variants. Our findings are especially relevant to populations similar to South Africa with low SARS-CoV-2 vaccine coverage and a dominant contribution of immunity from prior infection. Looking forward, the study provides context for anticipating the long-term circulation of SARS-CoV-2 in populations no longer naïve to the virus.
南非是最早检测到严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株的国家之一。由于其传播性增强和免疫逃逸特性,奥密克戎在出现后的3个月内就取代了其他全球流行的变异株。由于检测有限、奥密克戎的临床严重程度减弱以及再感染风险增加,奥密克戎BA.1和BA.2亚变体(BA.1/2)浪潮的规模在南非和许多其他国家仍知之甚少。利用自大流行开始以来密切监测的南非城市和农村队列的数据,我们分析了在奥密克戎BA.1/2浪潮之前、期间和之后收集的连续血清样本,以推断感染率并监测参与者免疫史随时间的变化。在农村队列中,奥密克戎BA.1/2感染发病率达到65%(95%置信区间,60% - 69%),在城市队列中达到58%(95%置信区间,61% - 74%),重复感染和疫苗突破感染在两个地点的所有感染中占比均超过60%。结合之前在同一队列中收集的关于奥密克戎变异株出现之前的感染数据,我们在奥密克戎BA.1/2浪潮之后确定了14种不同类别的SARS-CoV-2抗原暴露史,这表明免疫格局特别分散。很少有人(<6%)对SARS-CoV-2仍无感染史,且在两个队列地点,没有任何一种暴露史类别占人口的比例超过25%。此外,与德尔塔浪潮相比,队列参与者在奥密克戎BA.1/2浪潮期间感染的可能性是其两倍多。先前感染原始毒株(带有D614G突变)、贝塔和德尔塔变异株分别对奥密克戎BA.1/2感染提供了13%(95%置信区间,-21% - 37%)、34%(95%置信区间,17% - 48%)和51%(95%置信区间,39% - 60%)的保护作用。混合免疫(先前感染和接种疫苗)以及多次先前感染(未接种疫苗)分别将奥密克戎BA.1/2感染风险降低了60%(95%置信区间,42% - 7)和85%(95%置信区间,76% - 92%)。再感染和疫苗突破感染的传播风险比初次感染低41%(95%置信区间,26% - 53%)。我们的研究揭示了迅速变化的群体免疫格局,以及SARS-CoV-2不断变化的特征,以及这些因素如何相互作用以影响新出现变异株的传播。我们的研究结果对于类似于南非的人群尤其相关,这些人群的SARS-CoV-2疫苗接种率较低,且先前感染产生的免疫力占主导。展望未来,该研究为预测SARS-CoV-2在对该病毒不再易感的人群中的长期传播提供了背景信息。